# An Efficacy and Safety Study of Hydromorphone Hydrochloride (HCl) Oral Osmotic System (OROS) in the Reduction of Breakthrough Pain Medication Frequency in Participants With Cancer

> **NCT01006356** · PHASE4 · COMPLETED · sponsor: **Janssen Korea, Ltd., Korea** · enrollment: 141 (actual)

## Conditions studied

- Cancer
- Pain

## Interventions

- **DRUG:** Hydromorphone HCl OROS

## Key facts

- **NCT ID:** NCT01006356
- **Lead sponsor:** Janssen Korea, Ltd., Korea
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-10
- **Primary completion:** 2009-08
- **Final completion:** 2009-08
- **Target enrollment:** 141 (ACTUAL)
- **Last updated:** 2013-08-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01006356

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01006356, "An Efficacy and Safety Study of Hydromorphone Hydrochloride (HCl) Oral Osmotic System (OROS) in the Reduction of Breakthrough Pain Medication Frequency in Participants With Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01006356. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*